Bioavalaibility and pharmacokinetic comparison of two formulations of metformin 850 mg tablets in healthy Colombian volunteers

Colombia Medica

Volumn 42, Issue 1, 2011, Pages 81-87

  Holguín, Gloria ^a   Cuesta, Fanny ^a   Archbold, Rosendo ^a   Restrepo, Margarita ^a   Parra, Sergio ^a   Peña, Lina ^a   Montoya, Blanca ^a   Ríos, Juan Carlos ^a   Toro, Victoria Eugenia ^a   Ruiz, Adriana ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Area under curve; Bioavailability; Bioequivalence; Interchange of drugs; Metformin; Pharmacokinetics

Indexed keywords

GENERIC DRUG; METFORMIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; EPIGASTRIC PAIN; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 79953000422     PISSN: 01208322     EISSN: 16579534     Source Type: Journal    
DOI: 10.25100/cm.v42i1.754     Document Type: Article

References (21)

1. Dunn CJ, Peters DJ. Metformin. A review of its pharmacological properties and therapeutic use in non-insulindependent diabetes mellitus. Drugs. 1995; 49: 721-49.
2. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996; 30: 359-71. (Pubitemid 26177181)
3. Pentikainen PJ. Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet and three sustained release products. Int J Clin Pharmacol Ther Toxicol. 1986; 24: 213-20. (Pubitemid 16113669)
4. Hale TW, Kristensen LP, Hackett LP, Kohan R, Ilett KF. Transfer of metformin into human milk. Diabaetologia. 2002; 1509-14.
5. Najib N, Idkaidek N, Beshtawi M, Bader M, Admour I, Alam SM, et al. Bioequivalence evaluation of two brands of metformin 500 mg tablets (dialon1 & glucophage1) in healthy human volunteers. Biopharm Drug Dispos. 2002; 23: 301-6. (Pubitemid 35203430)
6. Zapater P, Horga JF. Bioequivalencia y genéricos. Los estu dios de bioequivalencia. I Una aproximación a sus bases teóricas, diseño y realización. Rev Neurol. 1999; 29: 1235-46.
7. Julious S. Tutorial in biostatistics. Sample sizes for clinical trials with normal data. Stat Med. 2004; 23: 1921-86.
8. Yuen KH, Peh KK. Simple high-performance liquid chromatographic method for the determination of metformin in human plasma. J Chromatogr B Biomed Appl. 1998; 710: 243-46. (Pubitemid 28318161)
9. Food and Drug Administration (FDA). 2001. Guidance for Industry. Bioanalytical Method Validation. [Accessed 25 Nov 2009]. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM070107.pdf
10. Food and Drug Administration (FDA). 2001. Guidance for Industry - Statistical Approaches to Establishing Bioequivalence. [Accessed 25 Nov 2009]. Available: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf
11. Food and Drug Administration (FDA) 2003. Guidance for industry, bioavailability and bioequivalence. Studies for orally administered drug products-general considerations. [Accessed 24 Nov 2009] Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM070124.pdf
12. Sambol NC, Chiang J, O'Conner M, Liu CY, Lin ET, Goodman AM, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol. 1996; 36: 1012-21. (Pubitemid 27014728)
13. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996; 30: 359-71. (Pubitemid 26177181)
14. Atanasova I, Bozhinova K, Todorova D, Terziivanov D. Pharmacokinetics and comparative bioavailability of two metformin formulations after single-dose administration in healthy subjects. Clin Drug Invest. 2003; 23: 743-9. (Pubitemid 37373796)
15. Vlahov V, Thyroff-Friesinger U, Koytchev R, Bakracheva N, Gatchev E. Bioequivalence studies with metformin: comparability of reference tablets from different origins. Int J Clin Pharmac Ther. 2005; 43: 457-62. (Pubitemid 41309606)
16. Cuesta F, Holguín G, Archbold R, Restrepo M, Peña L, Montoya B. et al. Bioequivalencia de dos formulaciones de metformina, tabletas con 850 mg, en voluntarios sanos colombianos. IATREIA. 2005; 18: 289-301. (Pubitemid 41695278)
17. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996; 334: 574-9.
18. Pacanowski MA, Hopley CW, Aquilante CL. Inter-individual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms. Expert Opin Drug Metabolism Toxicol. 2008; 4: 529-44. (Pubitemid 351890737)
19. Marathe P, Wen Y, Norton J, et al. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol. 2000; 50: 325-32.
20. Cheng CL, Yu LX, Lee HL, Yang CY, Lue CS, Chou CH. Biowaiver extension to BCS class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. Eur J Pharm Sci. 2004; 22: 297-304.
21. Yuen KH, Wong JW, Billa N, Julianto T, Toh WT. Bioequivalence of a generic metformin tablet preparation. Int J Clin Pharmac Ther. 1999; 37: 319-22. (Pubitemid 29338487)